Spotlight
Video

Pembrolizumab Survival Data: Minority Of Patients Are Surviving Beyond 4-5 Years, Checkpoint Inhibitors Are Giving Treatment Options That We Never Had

Loading........
Description: Hossein Borghaei DO, MS @HosseinBorghaei Of Fox Chase Cancer Center discusses Pembrolizumab Survival Data: Minority Of Patients Are Surviving Beyond 4-5 Years, Checkpoint Inhibitors Are Giving Treatment Options That We Never Had.
Shared By : Annual-Meeting
Posted on : 06/03/19
Added : 3 months ago